Investigation of brain tumours with 99mTc-MIBI SPET

Quarterly Journal of Nuclear Medicine

Volumn 46, Issue 4, 2002, Pages 336-345

  Baldari, S ^a   Restifo, G ^a   Cosentino, S ^a   Minutoli, F ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Brain neoplasms, radionuclide imaging; Glioma; Neoplasms; P glycoprotein; Radiation injuries; Recurrence; Technetium 99mTc sestamibi; Tomography, emission computed, single photon

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TRACER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN INJURY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG RESPONSE; GLIOBLASTOMA; GLIOMA; HUMAN; LYMPHOMA; MENINGIOMA; METASTASIS; MULTIDRUG RESISTANCE; NEUROMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RADIATION INJURY; RADIATION NECROSIS; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE LEVEL; TREATMENT FAILURE; TUMOR RECURRENCE;

BRAIN NEOPLASMS; HUMANS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0036892936     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Del Sole A, Falini A, Ravasi L, Ottobrini L, De Marchis D, Bombardieri E et al. Anatomical and biochemical investigation of primary brain tumours. Eur J Nucl Med 2001;28:1851-72.
2. Connolly LP, Drubach LA, Ted Treves S. Applications of nuclear medicine in pediatric oncology. Clin Nucl Med 2002;27:117-25.
3. Piwnica-Worms D, Holman BL. Non-cardiac applications of hexakis(alkylisonitrile) technetium-99m complexes. J Nucl Med 1990;31:1166-7.
4. 99mTc-sestamibi in oncology. Tumori 1996;82:12-21.
5. 99mTc-MIBI SPECT. J Nucl Med 1987;30:845.
6. O'Tuama LA, Treves ST, Larar JN, Packard AB, Kwan AJ, Barnes PD et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumours: A within-subject comparison. J Nucl Med 1993;34:1045-51.
7. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mitochondrial and plasmamembrane potential dependence. Circulation 1990;82:1826-38.
8. Piwnica-Worms D, Kronauge JF, Chiu ML. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med 1991;32:1992-9.
9. Chiu M, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2 methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-53.
10. 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model. Nucl Med Biol 1997;24:21-5.
11. 99mTc-MIBI and 201 Tl by a 9L gliosarcoma tumor model in rats. Nucl Med Biol 1993;20:773-6.
12. Crane P, Laliberte R, Heminway S. Effect of mitochondrial viability and metabolism of technetium-99m-sestamibi. Eur J Nucl Med 1993;20:20-5.
13. Parodi O. Thallium-201 and sestamibi: Principles and kinetics of the two tracers. J Ital Cardiol 1991;21:885-8.
14. 99mTc-methoxy-isobutyl-isonitrile (MIBI) in humans. Eur J Nucl Med 1989;15:597-600.
15. Delmon-Moingeon LI, Piwnica-Worms D, Van Den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis (2-methoxyisobutylisonitrile) technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198-202.
16. 99mTc sestamibi uptake by normal and neoplastic cell lines. Rev Med Chir Soc Med Nat Iasi 1995;99:116-23.
17. Staudenherz A, Fazeny B, Marosi C, Nasel C, Hoffmann M, Puig S et al. Does (99m)Tc-Sestamibi in high grade malignant brain tumors reflect blood-brain barrier damage only? Neuroimage 2000;12:109-11.
18. O'Tuama LA, Packard AB, Treves ST. SPECT imaging of pediatric brain tumor with hexakis (methoxyisobutylisonitrile) technetium (I). J Nucl Med 1990;31:2040-1.
19. 99mTc-MIBI for the diagnosis of gliomas. Rev Med Chir Soc Med Nat Iasi 1995;99:99-107.
20. Shih WJ, Kadzieclawa K, Lee C, Moody EB, Ryo UY. Technetium-99m-sestamibi uptake by cerebellar metastasis from bronchogenic carcinoma. Clin Nucl Med 1993;18:887-90.
21. Baillet G, Albuquerque L, Chen Q, Poisson M, Delattre JY. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. Eur J Nucl 1994;21:1061-6.
22. 99mTc-sestamibi. Nucl Med Commun 1995;16:258-64.
23. 201Tl and relation with P-glycoprotein. Clin Nucl Med 1999;24:765-72.
24. Soler C, Beauchesne P, Maatougui K, Schmitt T, Barral FG, Michel D et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998;25:1649-57.
25. 201Tl and predictivity of therapeutic effect. Kaku Igaku 1998;35:121-30.
26. Tomura N, Hirano H, Watanabe O, Kato K, Sasaki K, Watarai J et al. Preliminary results with Technetium-99m MIBI SPECT imaging in patients with brain tumors: Correlation with histological and neuroradiological diagnoses and therapeutic response. Comput Med Imaging Graph 1997;21:293-8.
27. 99mTc-MIBI useful in the diagnosis of local recurrence in patients with malignant gliomas? Cancer Radiother 1998;2:42-8.
28. Ambrus E, Kuncz A, Janoki G, Voros E, Szakall S, Balkay L et al. Evaluation of the nature of brain tumors using methods of nuclear medicine. Orv Hetil 1999;140:1979-83.
29. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22.
30. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M et al. Cerebral glioma: Evaluation with methionine PET. Radiology 1993;186:45-53.
31. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998;25:1261-9.
32. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-9.
33. Maffioli L, Gasparini M, Chiti A, Gramaglia A, Mogioj V, Pozzi A et al. Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 1996;23:308-11.
34. 99mTc-HMPAO uptake on recurrent occipital meningioma on brain SPECT images. J Nucl Med 1996;37:1183-5.
35. Lamy-Lhullier C, Dubois F, Blond S, Lecouffe P, Steinling M. Importance of cerebral tomoscintigraphy using technetium-labeled sestamibi in the differential diagnosis of recurrent tumor vs radiation necrosis in subtentorial glial tumors in the adult. Neurochirurgie 1999;45:110-7.
36. 99mTc-sestamibi SPET? Eur J Nucl Med 1998;25:401-9.
37. 201Tl chloride SPET in patients with malignant brain tumors. Nucl Med Commun 2001;22:631-9.
38. 201Tl. Neuroradiology 2001;43:1023-30.
39. 99mTc(m)-sestamibi SPET brain imaging for differentiating intracranial lymphoma from non-malignant lesions in AIDS patients. Nucl Med Commun 1998;19:47-53.
40. De La Pena RC, Ketonen L, Villanueva-Meyer J. Imaging of brain tumors in AIDS patients by means of dual-isotope thallium-201 and technetium-99m sestamibi single-photon emission tomography. Eur J Nucl Med 1998;25:1404-11.
41. 99mTc-MIBI brain SPECT of cerebellopontine angle tumors. Clin Nucl Med 1996;21:375-8.
42. 99mTc HMPAO accumulation in primary and metastatic brain tumors assessed by brain SPECT. Neurol Neurochir Pol 1998;32:1099-106.
43. Andrews DW, Das R, Kim S, Zhang J, Curtis M. Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistence. Neurosurgery 1997;40:1323-32.
44. 201Tl. Clin Nucl Med 1999;24:868-73.
45. Ohgaki H, Schauble B, Zur Hausen A, Von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995;427:113-8.
46. Ng HK, Lam PY. The molecular genetics of central nervous system tumors. Pathology 1998;30:196-202.
47. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. Br J Neurosurg 1999;13:299-305.
48. Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988;38:1371-4.
49. Beauchesne P, Soler C, Mosnier JF. Diffuse vertebral body metastasis from a glioblastoma multiforme: A technetium-99m Sestamibi single-photon emission computerized tomography study. J Neurosurg 2000;93:887-90.
50. 201Tl findings. Clin Nucl Med 1998; 23: 446-59.
51. Berry I, Gaillard JF, Guo Z, Cordoliani YS, Massip P, Manelfe C et al. Cerebral lesions in AIDS: What can be expected from scintigraphy? Cerebral tomographic scintigraphy using thallium-201: A contribution to the differential diagnosis of lymphomas and infectious lesions. J Neuroradiol 1995;22:218-28.
52. 99mTc-MIBI uptake in a primitive leptomeningeal melanoma. Eur J Dermatol 1998;8:169-72.
53. Tosaka M, Tamura M, Oriuchi N, Horikoshi M, Joshita T, Sugawara K et al. Cerebrospinal fluid immunocytochemical analysis and neuroimaging in the diagnosis of primary leptomeningeal melanoma. Case report. J Neurosurg 2001;94:528-32.
54. 99mTc-MIBI scintigraphy. Melanoma Res 1998;8:355-60.
55. Moretti JL, Duran Cordobes M, Starzec A, De Beco V, Vergote J, Benazzouz F et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nucl Med 1998;39:1214-8.
56. 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 1998;252:140-6.
57. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998;77:353-8.
58. Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF et al. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000;27:1786-92.
59. Mousseau M, Chauvin C, Nissou MF, Chaffanet M, Plantz D, Pasquier B et al. A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 1993;29A:753-9.
60. Matsumoto T, Tani E, Kaba K, Shindo H, Miyaji K. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 1991;72:460-6.
61. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-87.
62. 99mTc-MIBI SPECT, CT and MRI. Clin Nucl Med 1995;20:557-8.
63. Lass P. Discordant uptake of MIBI and HMPAO. J Nucl Med 1997;38:828.
64. 99mTC-MIBI brain SPET of an acoustic schwannoma. Clin Nucl Med 1994;19:152-4.
65. 99mTc-MIBI uptake in a pineocytoma. Clin Nucl Med 1998;23:771-3.
66. 201Tl scintigraphy. J Nucl Cardiol 2002;9:33-40.
67. Petretta M, Acampa W, Cuocolo A. Myocardial viability assessment in regions of left ventricular dysfunction. Part I: Radionuclide imaging and clinical implications. Nucl Med Commun 607-11.
68. 99mTc-MIBI brain SPECT in the diagnosis of recurrent glioma. Clin Nucl Med 1994;19:57-8.
69. Townsend DW, Cherry SR. Combining anatomy and function: The path to true image fusion. Eur Radiol 2001;11:1968-74.
70. Mongioj V, Brusa A, Loi G, Pignoli E, Gramaglia A, Scorsetti M et al. Accuracy evaluation of fusion of CT, MR, and spect images using commercially available software packages (SRS PLATO and IFS). Int J Radiat Oncol Biol Phys 1999;43:227-34.
71. Vikhoff-Baaz B, Bergh AC, Starck G, Ekholm S, Wikkelso C. A new set of fiducial markers for MRI, CT and SPET alignment. Nucl Med Commun 1997;18:1148-54.